A Study of Alveolar-Capillary Recruitment as a Screening and Tracking Tool for Patients with Pulmonary Arterial Hypertension
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 14-009439
- Scottsdale/Phoenix, Arizona: 14-009439
Sponsor Protocol Number: 14-009439
About this study
The purpose of this study is to determine if non-invasive measurement of blood flow to the lungs and the movement of gas from the lungs to the blood stream at rest and in response to low to moderate intensity exercise can be used as an assessment tool to allow for earlier detection and monitoring of individuals with pulmonary-arterial hypertension, and the response to drug treatments.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria
- Aim 1 PAH patients
- Diagnosed as having Group 1 PAH
- Idiopathic
- Hereditary
- Drug or toxin induced
- Associated with connective tissue disease
- Confirmation of PAH by right heart catheterization
- Capacity to consent
- Aim 2 PAH patients
- Physician approves the prescription of ambrisentan
- Equal number that have/do not have other medications for PAH
-
Healthy controls
- Free of any cardiovascular or pulmonary disease
- Not currently taking any medication
- Age- and sex-matched to PAH subjects
- Capacity to consent
Exclusion Criteria
- Receiving subcutaneous prostanoids
- Other medications (oral phosphodiesterase type 5 inhibitors, oral or inhaled prostanoids, calcium channel blockers, or l-arginine) allowed as long as subject has been taking them for at least 3 months prior to commencing study
- Pregnant or considering trying to become pregnant during enrollment in the study
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Rochester, Minn.
Mayo Clinic principal investigator Bruce Johnson, Ph.D. |
Closed for enrollment |
|
Scottsdale/Phoenix, Ariz.
Mayo Clinic principal investigator Bruce Johnson, Ph.D. |
Closed for enrollment |
|
More information
Publications
Publications are currently not available